Related Experiment Video
Updated: Feb 12, 2026
15:07
VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma
Published on: December 28, 2015
27.3K
Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a multicenter retrospective
Jung Yong Hong1,2, Dok Hyun Yoon1, Cheolwon Suh1
1Department of Oncology, Asan Medical Center, Ulsan University College of Medicine, Seoul, South Korea.
Annals of Hematology
|April 6, 2018
Summary
Bendamustine plus rituximab (BR) demonstrated a 55.1% overall response rate in Korean patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL). While effective, higher rates of hematological toxicities like neutropenia and thrombocytopenia were observed.
Area of Science:
- Hematology
- Oncology
- Clinical Trials
Background:
- Bendamustine plus rituximab (BR) is established for indolent lymphomas and mantle cell lymphoma.
- Real-world data on BR in diffuse large B cell lymphoma (DLBCL), particularly in Korean populations, is limited.
Purpose of the Study:
- To evaluate the efficacy and safety of bendamustine plus rituximab (BR) in Korean patients with relapsed or refractory DLBCL.
- To assess treatment outcomes and toxicity profiles in patients ineligible for intensive chemotherapy or autologous stem cell transplantation.
Main Methods:
- An observational, multicenter, retrospective analysis of 58 Korean patients with relapsed/refractory DLBCL treated with BR between December 2011 and December 2015.
- Patients received intravenous rituximab (375 mg/m²) followed by bendamustine (120 or 90 mg/m²) on subsequent days.
- Data collected included response rates, duration of response, progression-free survival (PFS), overall survival (OS), and adverse events.
Main Results:
- The overall response rate (ORR) was 55.1% (31.0% complete response, 24.1% partial response).
- Median progression-free survival was 3.9 months, and median overall survival was 6.7 months.
- The most frequent grade 3/4 adverse events were neutropenia (68.9%) and thrombocytopenia (58.6%). Febrile neutropenia occurred in 18.9% of patients.
Conclusions:
- Bendamustine plus rituximab (BR) shows significant efficacy in Korean patients with relapsed or refractory DLBCL.
- The treatment is associated with acceptable toxicity, although a higher incidence of grade 3/4 hematological toxicities warrants close monitoring in this population.
Related Concept Videos
01:12Diffusion
221.8K
Diffusion is the passive movement of substances down their concentration gradients—requiring no expenditure of cellular energy. Substances, such as molecules or ions, diffuse from an area of high concentration to an area of low concentration in the cytosol or across membranes. Eventually, the concentration will even out, with the substance moving randomly but causing no net change in concentration. Such a state is called dynamic equilibrium, which is essential for maintaining overall...
221.8K
01:21Diffusion
6.5K
Diffusion is a type of passive transport. In passive transport, a substance tends to move from an area of high concentration to an area of low concentration until the concentration is equal across the space. For example, take the diffusion of substances through the air. When someone opens a perfume bottle in a room filled with people, the perfume is at its highest concentration in the bottle and is at its lowest at the edges of the room. The perfume vapor will diffuse, or spread away, from the...
6.5K
01:16Facilitated Diffusion
1.3K
The plasma membrane, a critical structure in cellular biology, houses an array of transporters, or carrier proteins, interspersed within its lipid bilayer. These proteins play a crucial role in solute transport through facilitated diffusion, a form of passive diffusion that uses transporters to move the molecules across the membrane.
In this process, substrates such as organic compounds and ions interact with a transporter on one side, triggering conformational changes in proteins that enable...
In this process, substrates such as organic compounds and ions interact with a transporter on one side, triggering conformational changes in proteins that enable...
1.3K
03:48Behavior of Gas Molecules: Molecular Diffusion, Mean Free Path, and Effusion
31.4K
Although gaseous molecules travel at tremendous speeds (hundreds of meters per second), they collide with other gaseous molecules and travel in many different directions before reaching the desired target. At room temperature, a gaseous molecule will experience billions of collisions per second. The mean free path is the average distance a molecule travels between collisions. The mean free path increases with decreasing pressure; in general, the mean free path for a gaseous molecule will be...
31.4K
01:24Protein Diffusion in the Membrane
5.7K
Proteins show rotational as well as lateral diffusion across the membrane. The lateral diffusion of proteins was confirmed through the cell fusion experiment where mouse and human cells were fused, resulting in hybrid cells. When the human and mouse cells fused, the specific membrane proteins on human and mouse cells were marked with the red and green-fluorescent markers, respectively. Initially, the red and green fluorescence was located on the respective hemisphere of the cell. As time...
5.7K
01:17Assessment of Diffusion and Perfusion
1.7K
Understanding and evaluating diffusion and perfusion is critical in assessing a patient's respiratory and circulatory health. These processes play key roles in maintaining the body's internal environment, ensuring that tissues receive adequate oxygen while waste products are efficiently removed.
The Role of Diffusion in Respiration
Diffusion is the process by which molecules move from an area of higher concentration to an area of lower concentration. In the respiratory system, this...
The Role of Diffusion in Respiration
Diffusion is the process by which molecules move from an area of higher concentration to an area of lower concentration. In the respiratory system, this...
1.7K